DK0954290T3 - Farmaceutisk tablet med kontrolleret frigivelse indeholdende en bærer baseret på tværbundet amylose og hydroxypropylmethylcellulose - Google Patents

Farmaceutisk tablet med kontrolleret frigivelse indeholdende en bærer baseret på tværbundet amylose og hydroxypropylmethylcellulose

Info

Publication number
DK0954290T3
DK0954290T3 DK97915220T DK97915220T DK0954290T3 DK 0954290 T3 DK0954290 T3 DK 0954290T3 DK 97915220 T DK97915220 T DK 97915220T DK 97915220 T DK97915220 T DK 97915220T DK 0954290 T3 DK0954290 T3 DK 0954290T3
Authority
DK
Denmark
Prior art keywords
cross
linked amylose
tablet containing
hydroxypropylmethylcellulose
controlled
Prior art date
Application number
DK97915220T
Other languages
Danish (da)
English (en)
Inventor
Francois Chouinard
Wilfrid Jacques
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc filed Critical Labopharm Inc
Application granted granted Critical
Publication of DK0954290T3 publication Critical patent/DK0954290T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97915220T 1996-04-10 1997-04-04 Farmaceutisk tablet med kontrolleret frigivelse indeholdende en bærer baseret på tværbundet amylose og hydroxypropylmethylcellulose DK0954290T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002173818A CA2173818A1 (fr) 1996-04-10 1996-04-10 Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
PCT/CA1997/000229 WO1997037639A1 (fr) 1996-04-10 1997-04-04 Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Publications (1)

Publication Number Publication Date
DK0954290T3 true DK0954290T3 (da) 2003-09-22

Family

ID=4157953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97915220T DK0954290T3 (da) 1996-04-10 1997-04-04 Farmaceutisk tablet med kontrolleret frigivelse indeholdende en bærer baseret på tværbundet amylose og hydroxypropylmethylcellulose

Country Status (22)

Country Link
US (1) US5885615A (zh)
EP (1) EP0954290B1 (zh)
JP (1) JP4166278B2 (zh)
KR (1) KR100439614B1 (zh)
CN (1) CN1218396A (zh)
AT (1) ATE240719T1 (zh)
AU (1) AU711089B2 (zh)
BR (1) BR9708772A (zh)
CA (1) CA2173818A1 (zh)
CZ (1) CZ294342B6 (zh)
DE (1) DE69722247T2 (zh)
DK (1) DK0954290T3 (zh)
ES (1) ES2200166T3 (zh)
IL (1) IL126477A (zh)
MY (1) MY115535A (zh)
NO (1) NO321862B1 (zh)
NZ (1) NZ332576A (zh)
PL (1) PL187764B1 (zh)
PT (1) PT954290E (zh)
TR (1) TR199802034T2 (zh)
WO (1) WO1997037639A1 (zh)
ZA (1) ZA973054B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
EP1137403B1 (en) 1998-12-11 2009-03-11 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
EP1174127A1 (en) * 2000-07-21 2002-01-23 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Composition for targeted release of an actvie substance and process for producing such a composition
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
ES2399880T3 (es) * 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
RU2333745C2 (ru) * 2002-10-25 2008-09-20 Лабофарм Инк. Композиции с контролируемым высвобождением
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
MY142195A (en) * 2002-10-25 2010-10-15 Labopharm Inc Controlled-release compositions
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7691087B2 (en) * 2002-11-25 2010-04-06 Scimed Life Systems, Inc. Injection device
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
UA94916C2 (ru) * 2005-09-09 2011-06-25 Лабофарм Инк. Композиция тразодона для введения один раз в день
US20070065484A1 (en) * 2005-09-21 2007-03-22 Chudzik Stephen J In situ occlusion using natural biodegradable polysaccharides
US20070065483A1 (en) * 2005-09-21 2007-03-22 Chudzik Stephen J In vivo formed matrices including natural biodegradable polysaccharides and uses thereof
WO2007055329A1 (ja) * 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
US20080154241A1 (en) * 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
CA2723192A1 (en) 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
JP5638527B2 (ja) * 2008-09-04 2014-12-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ結合阻害剤の最適な送達のための安定な医薬組成物
JP5713911B2 (ja) * 2008-10-27 2015-05-07 アルザ・コーポレーシヨン 長期放出型経口アセトアミノフェン／トラマドール投与形態
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
NL9201196A (nl) * 1992-07-03 1994-02-01 Tno Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat.
AU668198B2 (en) * 1992-07-24 1996-04-26 Labopharm (Barbados) Limited Cross-linked polyhydroxylic material for enzymatically controlled drug release
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Also Published As

Publication number Publication date
DE69722247D1 (de) 2003-06-26
EP0954290B1 (fr) 2003-05-21
AU711089B2 (en) 1999-10-07
WO1997037639A1 (fr) 1997-10-16
NO984703D0 (no) 1998-10-08
NZ332576A (en) 2000-03-27
CZ294342B6 (cs) 2004-12-15
PL187764B1 (pl) 2004-10-29
KR100439614B1 (ko) 2004-10-14
ZA973054B (en) 1998-06-01
IL126477A (en) 2001-10-31
MY115535A (en) 2003-07-31
DE69722247T2 (de) 2004-04-01
IL126477A0 (en) 1999-08-17
EP0954290A1 (fr) 1999-11-10
NO984703L (no) 1998-12-08
US5885615A (en) 1999-03-23
CA2173818A1 (fr) 1997-10-11
TR199802034T2 (xx) 1999-02-22
ES2200166T3 (es) 2004-03-01
AU2283297A (en) 1997-10-29
PT954290E (pt) 2003-10-31
PL329285A1 (en) 1999-03-15
ATE240719T1 (de) 2003-06-15
KR20000005337A (ko) 2000-01-25
CN1218396A (zh) 1999-06-02
NO321862B1 (no) 2006-07-17
BR9708772A (pt) 2000-01-04
JP2000507561A (ja) 2000-06-20
JP4166278B2 (ja) 2008-10-15
CZ325498A3 (cs) 1999-03-17

Similar Documents

Publication Publication Date Title
DK0954290T3 (da) Farmaceutisk tablet med kontrolleret frigivelse indeholdende en bærer baseret på tværbundet amylose og hydroxypropylmethylcellulose
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
DE69636724D1 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
NZ510487A (en) Pharmaceutical composition comprising ciprofloxacin, sodium alginate, xanthan gum and a cross-linker polymer in a tablet or capsule form
DK1121099T3 (da) I maven hvilende farmaceutiske præparater til kontrolleret frigivelse
FI930509A0 (fi) Anvaendning av graensytpolymeriserade membraner i doseringsanordningar
ES2191066T3 (es) Preparacion enantioselectiva de sulfoxidos farmaceuticamente activos por biooxidacion.
NO20001219L (no) Blanding for medikament-administrasjon
AU7004194A (en) Drug system
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
BG103714A (en) Pararacetamol-containing tablet
CA2140032A1 (en) Cross-linked amylose material for enzymatically controlled drug release
ES8504127A1 (es) Procedimiento de preparar compuestos 1,4-dihidropiridinicos.
AU8121391A (en) Self-sticking matrix system for the sustained transcutaneous release of piribedil
PL296588A1 (en) Pellets made of thermally processible elastomeric block styrene-butadiene copolymers, containing active substance and method of obtaining such pellets
NO942228L (no) Ipsapiron-legemiddeltilberedning
HUP9902681A2 (hu) Térhálósított amilózt és hidroxi-propil-metil-cellulózt tartalmazó hordozóval készült szabályozott felszabadulású tabletta gyógyszerkészítmény
UA10108A (uk) Дитячий лікарський засіб "паравіт", який виявляє жарознижуючу та анальгетичну дію
DK302990D0 (da) Fremgangsmaade til nedbrydning af metal-cyanidkomplekser under anvendelse af mikrobielle enzymer